Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.

Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.

There is no current approved therapy for the ultimately lethal neuro- and cardio-degenerative disease Friedreich's ataxia (FA). Finding minimally-invasive molecular biomarkers of disease progression and drug effect could support smaller, shorter clinical trials. Since we and others have noted a...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Genki Hayashi, Gino Cortopassi
Format:	Artykuł
Język:	English
Wydane:	Public Library of Science (PLoS) 2016-01-01
Seria:	PLoS ONE
Dostęp online:	http://europepmc.org/articles/PMC4831832?pdf=render

Podobne zapisy

Sexual dimorphism in a mouse model of Friedreich’s ataxia with severe cardiomyopathy
od: Lili Salinas, i wsp.
Wydane: (2024-10-01)

Potential biomarker identification for Friedreich's ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion.
od: Marissa Z McMackin, i wsp.
Wydane: (2019-01-01)

Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich's Ataxia.
od: Mittal Jasoliya, i wsp.
Wydane: (2019-01-01)

Genetics and Friedreich Ataxia
od: J Gordon Millichap
Wydane: (2002-06-01)

Genetics of Friedreich Ataxia
od: J Gordon Millichap
Wydane: (1997-06-01)

Friedreich’s Ataxia: A Neuronal Point of View on the Oxidative Stress Hypothesis
od: Barbara Carletti, i wsp.
Wydane: (2014-09-01)

Molecular Defects in Friedreich’s Ataxia: Convergence of Oxidative Stress and Cytoskeletal Abnormalities
od: Frances M. Smith, i wsp.
Wydane: (2020-11-01)

Late-Onset Friedreich’s Ataxia
od: J Gordon Millichap
Wydane: (1993-08-01)

Friedreich’s Ataxia with Retained Reflexes
od: J Gordon Millichap
Wydane: (1995-04-01)

Friedreich's Ataxia and Glucose Metabolism
od: J Gordon Millichap
Wydane: (1988-08-01)

5-Hydroxytryptophan in Friedreich’s Ataxia
od: J Gordon Millichap
Wydane: (1995-06-01)

Iron Storage in Friedreich’s Ataxia
od: J Gordon Millichap
Wydane: (1999-08-01)

Tissue Iron in Friedreich Ataxia
od: Arnulf H Koeppen
Wydane: (2024-01-01)

Respiratory Function in Friedreich’s Ataxia
od: Elena Vinante, i wsp.
Wydane: (2022-08-01)

The pathogenesis of cardiomyopathy in Friedreich ataxia.
od: Arnulf H Koeppen, i wsp.
Wydane: (2015-01-01)

Is Friedreich ataxia an epigenetic disorder?
od: Kumari Daman, i wsp.
Wydane: (2012-01-01)

Epigenetic modification of the frataxin gene for the treatment of Friedreich’s ataxia
od: Vilema Enriquez, MG
Wydane: (2018)

Friedreich ataxia in a family from Mali, West Africa/Friedreich ataxia in a Malian family
od: Cheick A. K. Cissé, i wsp.
Wydane: (2021-05-01)

Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich’s Ataxia
od: Anusha Sivakumar, i wsp.
Wydane: (2022-05-01)

Antioxidant Therapies and Oxidative Stress in Friedreich’s Ataxia: The Right Path or Just a Diversion?
od: Laura R. Rodríguez, i wsp.
Wydane: (2020-07-01)

Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia.
od: Vincent Paupe, i wsp.
Wydane: (2009-01-01)

Exploring neuropsychiatric symptoms in Friedreich ataxia
od: Simona Karamazovova, i wsp.
Wydane: (2024-11-01)

Friedreichs ataxia in a diabetic patient
od: Inna Igorevna Klefortova, i wsp.
Wydane: (2010-06-01)

Friedreich's Ataxia – A Clinical Diagnosis
od: Md. Fekarul Islam, i wsp.
Wydane: (2015-01-01)

Clinical and Genetic Diagnosis of Friedreich’s Ataxia
od: J Gordon Millichap
Wydane: (1998-05-01)

Emerging antioxidant therapies in Friedreich’s ataxia
od: Fred Jonathan Edzeamey, i wsp.
Wydane: (2024-02-01)

An Overview of the Ferroptosis Hallmarks in Friedreich’s Ataxia
od: Riccardo Turchi, i wsp.
Wydane: (2020-10-01)

Perspectives on current models of Friedreich’s ataxia
od: Simge Kelekçi, i wsp.
Wydane: (2022-08-01)

Anaesthesia for a patient with Friedreich′s ataxia
od: Ilango Ganesan
Wydane: (2011-01-01)

Otoneurological Abnormalities in Patients with Friedreich's Ataxia
od: Bianca Simone Zeigelboim, i wsp.
Wydane: (2017-01-01)

Epigenetic-based therapies for Friedreich ataxia
od: Chiranjeevi eSandi, i wsp.
Wydane: (2014-06-01)

Predictors of loss of ambulation in Friedreich's ataxia
od: Christian Rummey, i wsp.
Wydane: (2020-01-01)

Hepatic mitochondrial dysfunction in Friedreich Ataxia
od: Stüwe Sven H, i wsp.
Wydane: (2011-11-01)

Prediction of the disease course in Friedreich ataxia
od: Christian Hohenfeld, i wsp.
Wydane: (2022-11-01)

Friedreich’s Ataxia-A Case Report
od: Tahreem Muntaha, i wsp.
Wydane: (2018-11-01)

Friedreich ataxia- pathogenesis and implications for therapies
od: Martin B. Delatycki, i wsp.
Wydane: (2019-12-01)

At-home wearable-based monitoring predicts clinical measures and biological biomarkers of disease severity in Friedreich’s Ataxia
od: Ram Kinker Mishra, i wsp.
Wydane: (2024-10-01)

Perspectives of the Friedreich ataxia community on gene therapy clinical trials
od: Shandra J. Trantham, i wsp.
Wydane: (2024-03-01)

Estrogen prevents oxidative damage to the mitochondria in Friedreich's ataxia skin fibroblasts.
od: Timothy E Richardson, i wsp.
Wydane: (2012-01-01)

Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich’s Ataxia Models
od: Rosella Abeti, i wsp.
Wydane: (2018-07-01)